Not yet recruiting
Analysis of histological risk factors and biomarkers in paediatric retinoblastoma
2024-515962-15-00· Phase 2· Institut Curie· Source
Recruiting
A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec
NCT07444450· Phase 3· Biogen· Source
Not yet recruiting
Phase I/II trial of Dinutuximab beta in combination with Irinotecan and Rapamycin in pediatric, adolescents and adult patients with relapsed/refractory bone tumors. BONE DINIRRA
2026-525463-40-00· Phase 1/2· Les Hopitaux Universitaires De Strasbourg· Source
Recruiting
A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluate the efficacy and safety of QVM149 (indacaterol acetate / glycopyrronium bromide / mometasone furoate) compared to salmeterol xinafoate/fluticasone propionate in children from 12 years to less than 18 years of age with asthma.
2022-502365-26-00· Phase 3· Novartis Pharma AG· Source
Recruiting
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
NCT07058077· Phase 2/3· Merck Sharp & Dohme LLC· Source
Recruiting
A Multi-Arm, Platform Trial For Relapsed Neuroblastoma
NCT07334301· Phase 1/2· University of Birmingham· Source
Active, not recruiting
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
2023-507655-30-00· Phase 3· Eli Lilly & Co.· Source
Active, not recruiting
STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
NCT06571383· Phase 4· Novo Nordisk A/S· Source
Not yet recruiting
Stopping Pneumonia Antibiotherapy Regimen Early
NCT06291012· Phase 4· University Hospital, Montpellier· Source
Recruiting
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
NCT05835310· Phase 3· AstraZeneca· Source
Recruiting
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
NCT05748171· Phase 2· Pfizer· Source
Active, not recruiting
Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials
NCT05335876· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
NCT05183035· Phase 3· PedAL BCU, LLC· Source
Recruiting
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
NCT05476939· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source
Active, not recruiting
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow
NCT05330325· Phase 3· Novo Nordisk A/S· Source
Recruiting
A phase 2/3, multicenter, randomized, double-blind study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of oral ozanimod (RPC1063) in pediatric subjects with moderately to severely active ulcerative colitis with an inadequate response to conventional therapy.
2023-509248-86-00· Phase 2/3· Bristol-Myers Squibb Services Unlimited Company· Source
Recruiting
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
NCT05156398· Phase 3· Pfizer· Source
Recruiting
International study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine
2022-501454-11-00· Phase 3· GPOH gGmbH· Source
Recruiting
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
NCT04221035· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source
Active, not recruiting
A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy
NCT04015141· Phase 2· Eisai Inc.· Source
Active, not recruiting
Phase II trial of nivolumab for pediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma, for evaluation of response in patients with progressive disease (Cohort 1) or as consolidative immunotherapy in patients in complete remission after relapse (Cohort 2) - NIVO ALCL
2024-516807-17-00· Phase 2· Institut Gustave Roussy· Source
Active, not recruiting
Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood
NCT03793478· Phase 1/2· Daiichi Sankyo· Source
Active, not recruiting
A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension
NCT03492177· Phase 2· Actelion· Source
Recruiting
Inotuzumab ozogamicin for Acute Lymphoblastic Leukemia
2023-504694-20-00· Phase 1/2· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source
Recruiting
rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma
2024-516078-31-00· Phase 2/3· The University Of Birmingham· Source
Active, not recruiting
Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma
NCT00470223· Phase 3· UNICANCER· Source